We report on the diagnostic validity of the serum concentrations of the C-terminal propeptide of type I procollagen (a marker of bone formation) and of the urinary excretion of deoxypyridinoline (a marker of bone resorption) in a consecutive series of 89 tumour patients who were routinely examined by 99m Tc-methylene bisphosphonate bone scintigraphy for detection of bone metastases.
Introduction
Type I collagen accounts for more than 90% of the or-Bone collagen is stabilized by the formation of pyridinganic matrix of bone and is synthesized in the form of ium cross-links between the terminal, non-helical part of a larger molecule, type I procollagen. This precursor type I collagen molecule and the helical region of anmolecule contains additional sequences at both ends other. The cross-links found in bone collagen are formed which are removed by specific proteinases before the from two hydroxylysine residues and one lysine residue collagen molecules are assembled into fibers. The part (= deoxypyridinoline) or from three hydroxylysine resiremoved from the carboxy^terminal end of the molecule dues (= pyridinoline). Deoxypyridinoline is found alenters the circulation where it can be measured by most exclusively in bone. The measurement of deoxyheterogeneous immunoassays (for review see I.e. (1) ). pyridinoline excretion in urine should therefore specifiThe concentration of this circulating C-terminal propep-cally reflect the degradation of bone collagen and hence tide is thought to be directly associated with the number bone resorption (3) . of type I collagen molecules formed. Therefore it can be At present only preliminary results are available regardused to quantify type I collagen synthesis and hence ing the clinical significance of markers of bone collagen bone formation (2) . metabolism in tumour patients (4-6).
Here we report on the diagnostic validity of the combined assessment of bone collagen synthesis and degradation with respect to detecting bone metastases in patients with different malignant tumours, comparing the results with those of bone scintigraphy. The values of the markers of bone collagen turnover were also compared with those of alkaline phosphatase and urinary calcium excretion which are the presently available measures for routine assessment of bone formation and resorption, respectively.
Determination of creatinine concentration in urine was performed using the fully mechanized analyzer Hitachi/BM 704 (Boehringer Mannheim GmbH, Mannheim, Germany) by employing a kinetic modification of the Jaffe procedure (7).
Urinary deoxypyridinoline excretion is given as μηιοΐ/ηιοί creatinine.
The following reference interval (2.5th-97.5th percentile) for excretion of deoxypyridinoline in second morning urine samples was established in apparently healthy pers'dhs (urine samples were obtained between 8.00 and 10.00 a.m.): 1.3-9.3 (median: 4.6) μπιοΐ/rnol creatinine (n = 99; 51 males and 48 females; range of age: 19-62 years), liiere was no dependence of reference values on sex (p > 0.1).
Materials and Methods
Characterization of patients by bone scintigraphy
We examined venous blood specimens and second morning urine samples from a consecutive series of patients (34 males, 55 females; range of age: 26-84 years) with malignant diseases who were routinely examined for the presence of bone metastases/primary bone tumours by 99m
Tc-methylene bisphosphonate bone scintigraphy. Samples were collected between 8:00 and 10:00 a.m.
The diagnoses of the patients were cancers of breast (n = 33), bronchia (n = 11), prostate (n = 7), kidney (n = 4), thyroid glands (n = 2), oesophagus (n = 2), colon (n = 2), pharynx (n = 2), tongue (n = 2), stomach (n = 1), tonsils (n = 1), uterus (n = 1) and parathyroid glands (n = 1) as well as malignant melanoma (n = 10), lymphoma (n = 5), Hodgkins's disease (n = 2), multiple myeloma (n = 1), osteosarcoma (n = 1) and Ewing's tumour (n = 1).
In compliance with the results of the scintigraphic examinations (as independently judged by two experienced physicians for nuclear medicine without knowledge of the corresponding biochemical data) the patients were divided into the following groups:
(1) There are no pathological findings (= group 0; n = 29).
(2) According to the pathological findings (being detectable by scintigraphy) the presence of bone metastases seems to be improbable (= group 1; n = 33), possible (= group 2; n = 13) and probable (= group 3; n = 14), respectively.
All procedures involving human subjects were in compliance with the Helsinki Declaration of 1975 (as revised in 1983).
Determination of the carboxy-terminal propeptide of procollagen type I in serum
The concentration of the carboxy-terminal propeptide of procollagen type 1 was determined by an enzyme immunoassay (Prolagen-C™; Metra Biosystems, Inc., Palo Alto, CA [U.S.A.]). A calibration curve was constructed by a 4-parameter curve fitting algorithm.
The following reference intervals (2.5th-97.5th percentile) for the C-terminal propeptide in serum were established in apparently healthy persons: (1) 50-180 μg/l (males, n = 51) (2) 50-145 μg/l (females, n = 51). Range of age was 23-58 years (males) and 23-59 years (females). The following reference intervals (2.5th-97.5th percentile) for bone alkaline phosphatase concentration in serum were established in apparently healthy persons: (1) 3.8-21.3 μ §/1 (males, η ^ 51) (2) 3.4-15.0 μg/l (females, n -51). Range of age was 20-55 years (males) and 18-56 years (females).
Determination of the urinary excretion of calcium
Calcium excretion in second morning urine samples (see above) was determined with an EFOX 5053 flame emission spectrometer (Eppendorf Ger tebau Netheler H-Hinz GmbH, Hamburg, Germany). Data are given in mol/mol creatinine (upper reference limit: 0.6 mol/mol).
Statistical analysis
The statistical methods employed inlcude the U-test according to Wilcoxon, Mann & Whitney (two-tailed) for unpaired samples, linear regression equations as well as linear correlation coefficients (9) . The discriminating power was estimated by calculating the Z scores (for explanations see tab. 1). The accuracy was determined as the area under the receiver-operating characteristic curve.
Results
Discriminating power of C-terminal propeptide concentrations and deoxypyridinoline excretion in different groups of patients Figure 1 shows the distributions of C-terminal propeptide concentrations and deoxypyridinoline excretion in the four groups of patients (as defined under Materials and Methods). Z score analysis reveals that the discriminating power of deoxypyridinoline is superior to that of calcium excretion whereas C-terminal propeptide concentrations are inferior to bone as well as total alkaline phosphatase values if groups 1, 2 and 3, respectively, are compared with group 0 (tab. 1). Four patients belonging to group 0 showed an increased urinary excretion of deoxypyridinoline (among them a patient with a carcinoma of the parathyroid glands). There was no significant difference in the γ-glutamyl transferase activity concentrations in the four groups of patients (p > 0.05).
Relationship between the examined biochemical markers of bone metabolism
There was a correlation (r = + 0.398; p < 0.0001) between C-terminal propeptide concentrations and deoxypyridinoline excretion values in the group of 89 patients examined. The same applies to the relationship between C-terminal propeptide values and bone alkaline phosphatase concentrations (p < 0.0001).
Apart from one patient with primary hyperparathyroidism all patients were normocalcaemic. None of the urine samples examined showed a urinary excretion of calcium above the upper reference limit. A lack of correlation was found between calcium excretion and all other markers of bone resorption as well as bone formation (tab. 2). Receiver-operating characteristic (ROC) plots for C-terminal propeptide concentrations and deoxypyridinoline excretion
To evaluate the efficacy of the bone collagen metabolism markers for discriminating between groups 0 and 1 on the one hand and groups 2 and 3 on the other, threshold values were fixed corresponding to.· the 10th, 20th, ..., 90th percentile of the distribution of C-terminal propeptide concentrations and deoxypyridinoline excretion in the group of 89 patients examined ( fig. 3 ). For the combination of the two markers an increase of at least one marker above the 10th, 20th, ..., 90th percentile (see above) was defined as a positive test result.
The accuracy was 0.82 for C-terminal propeptide values and 0.75 for deoxypyridinoline excretion; a combination of both markers did not further increase the value of accuracy (0.82) compared with the determination of Cterminal propeptide concentrations alone.
At a threshold value of 100 μg/l C-terminal propeptide and of 7.7 μηιοΐ/mol creatinine for deoxypyridinoline (corresponding to the 60th percentiles; see above) the diagnostic efficiency (= sum of diagnostic sensitivity and diagnostic specificity) for the combination of both Fig. 3 Receiver-operating characteristic (ROC) analysis of C-terminal propeptide concentrations (indicated by circles), the urinary excretion of deoxypyridinoline (designated by stars) and the combination of both markers (indicated by squares) in patients belonging to groups 2 and 3 (= according to scintigraphic criteria the presence of bone metastases seems to be possible or probable) (n = 27) vs patients belonging to groups 0 and 1 (= according to scintigraphic criteria there are no pathological findings or the presence of bone metastases seems to be improbable) (n = 62). Threshold values were fixed corresponding to the 10th, 20th, ..., 90th percentile of the distribution of C-terminal propeptide concentrations and deoxypyridinoline excretion in the group of 89 patients examined. For the combination of the two markers an increase of at least one marker above the 10th, 20th, ..., 90th percentile was defined as a positive test result. For these threshold values the diagnostic sensitivities as well as the diagnostic specificities were calculated.
Bur J Clin Chem Clui Biochem 1995; 33 (No 8) markers was found to be maximal. For these threshold values the diagnostic sensitivity was 93%; the diagnostic specificity was 55%; the predictive value of a positive test result was 47%; and the predictive value of a negative test result was 94%. The prevalence of patients belonging to groups 2 and 3 was 30%.
Discussion
It has previously been shown in patients with various types of metabolic bone diseases that the serum concentrations of the C-terminal propeptide correlate with histomorphometric variables of bone formation (2) . Both in cancer patients (6) as well as in patients with metabolic bone diseases (2) a correlation of the C-terminal propeptide values with alkaline phosphatase activities was found.
For the interpretation of C-terminal propeptide data it has to be taken into account that a disturbed liver function may yield high serum concentrations probably due to the involvement of liver endothelial cells in the metabolic clearance of this molecule (2) . In the present study a major influence of liver function upon C-terminal propeptide values can be excluded because no statistically significant changes of γ-glutamyl transferase activity concentrations were found between the patient groups examined.
The reference interval for C-terminal propeptide serum concentrations established by us essentially corresponds to that previously described for a radioimmunoassay method (1).
Our results show a high discriminating power of bone alkaline phosphatase values for differentiating between patients with and those without bone metastases, in contrast to the results of van Hoff et al. (10) as well as Stieber et al. (11) who found no such statistically significant difference. This difference may be due to the different localization of the primary tumours as well as due to the different character of the bone lesions (osteoblastic, osteolytic and mixed, respectively). Burlina et al. (12) reported that the determination of bone alkaline phosphatase using wheat-germ lectin precipitation is more specific than total alkaline phosphatase in the identification of bone metastases whereas Cooper et al. (13) showed that bone alkaline phosphatase mass concentrations (as determined immuno-radiometrically) may be elevated in patients with bone metastases while total alkaline phosphatase activities remain in the normal range. In the present study Z score analysis revealed that bone alkaline phosphatase has a higher discriminating power than total alkaline phosphatase with respect to differentiating between patients with and those without bone metastases. This corresponds to previous findings of Garnero & Delmas (14) .
Osteocalcin, which is another marker of bone formation, has also been found to be elevated in patients with bone metastases (15, 16) . Interestingly, a lack of correlation has been shown in these patients between osteocalcin levels and bone alkaline phosphatase values (12) . However, two drawbacks of this measurable quantity have to be taken into account when comparing the values with those of bone alkaline phosphatase concentrations:
(a) Decreased renal function may cause increased values of this analyte due to its low relative molecular mass (17) .
(b) Osteocalcin concentrations are characterized by a marked diurnal rhythm (18) .
To our knowledge there are no examinations concerning other bone matrix proteins with respect to the diagnosis of bone metastases (e. g., osteonectin or proteoglycans [e.g. by employing the monoclonal antibody 5D4 against keratan sulfate]).
Bone formation and bone resorption (as assessed by the determination of bone collagen turnover) are coupled in the patients examined by us which is in concordance with previous findings in tumour patients (4).
The urinary excretion of calcium did not correlate with that of deoxypyridinoline, corresponding to findings in breast cancer patients undergoing therapy with inhibitors of osteoclast activity (19) . This strongly supports the hypothesis that calcium and deoxypyridinoline excretion reflect different facets of bone destruction.
Increased excretion values of deoxypyridinoline in four patients in spite of pathological findings being absent as assessed by bone scintigraphy (4, 5) may be explained as follows:
(a) one of these four patients showed primary hyperparathyroidism which causes increased values of deoxypyridinoline (20) .
(b) the increase of pyridinium cross-links excretion may reflect occult metastases for which the diagnostic sensitivity of bone scintigraphy is too low. proliferation and activity of osteoclasts and to produce osteolysis (e.g., transforming growth factors, prostaglandins, tumour necrosis factors and interleukin-1 that has previously been labelled Osteoclast-activatingfactor') (22) (23) (24) (25) . Further, osteoclast activation is a key step in the establishment and growths of all bone metastases (23) . However, it must be taken into consideration that all of these substances do act as paracrine factors so that measuring these mediators in blood seems to have minor diagnostic significance for monitoring of bone diseases.
For the interpretation of the data presented here the following aspects have to be taken into account:
(a) Detection of lesions by bone scintigraphy depends upon uptake of radioisotopes into areas of new bone formation whereas this method is not suitable for the sensitive detection of lytic lesions (for review see 1. c. (26)). To further enhance the diagnostic sensitivity bone scan scintigraphy should be supplemented by other techniques (e.g., bone marrow scintigraphy, nuclear magnetic resonance tomography and single photon emission computer tomography). On the other hand suspicious findings must be confirmed by X-ray examinations to enhance the diagnostic specificity.
(b) The tumour patients examined by us are heterogeneous with respect to the localization of the primary tumour as well as staging and grading which will affect the prevalence of bone metastases as well as the character of the metastatic bone lesions (osteoblastic, osteoclastic or mixed).
Comparison of patients with and those without bone metastases (as detected by bone scintigraphy) yielded a stat istically significant difference of the values of both biochemical markers but there is a substantial overlap of the values; for the urinary excretion of deoxypyridinoline this has already been observed in cancer patients (4, 5) .
• r
The urinary excretion of hydroxyproline has been proposed as an index of bone resorption for the diagnosis (27) and follow-up (28) of patients with malignant tumours. However, several drawbacks limit the clinical usefulness of this quantity for assessment of bone resorption:
(a) hydroxyproline is not exclusively derived from the bone;
(b) hepatic metabolism may alter urinary excretion values; (c) the urinary excretion depends both upon dietary uptake as well as upon the degradation of newly synthesized collagen (29) .
In patients with prostate cancer it has already been shown that serial measurements of the urinary excretion of pyridinium cross-links are suitable for monitoring of clinical progression (29) ; the same applies to the determination of bone alkaline phosphatase activity in patients with breast cancer (11) . Moreover, in patients with tumour-induced osteolysis the urinary excretion of pyridinium cross-links may be a useful quantity for monitoring therapy with agents inhibiting osteoclast activity (e.g., bisphosphonates) (19) .
